Latest Articles
-
Forecast Of The Day: Abbott’s Nutritionals Revenue
What? Abbott’s (NYSE:ABT) Nutritionals Revenue has risen from around $7.4 billion in 2019 to about $7.7 billion in 2020. Trefis expects the metric to rise to about $8.4 billion in 2021 and to about $8.7 billion in 2022. Why? We expect g...
-
This Pharma Stock Appears To Be A Better Pick Over Abbott Labs
We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Abbott Labs stock (NYSE: ABT) with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. LLY stock trades a...
-
Will Abbott Stock Rise After Its Q3 Results?
Abbott (NYSE:ABT) is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals busi...
-
With Covid-19 Cases Falling Again Will Abbott Stock See Higher Levels?
[Updated: Sep 29, 2021] Abbott Stock Decline The stock price of Abbott (NYSE:ABT) has seen a drop of 5% over the last one month (twenty-one trading days). It reached its 52-week high level of around $130 on September 13, before a slight decline ...
-
This Stock Is Likely To Outperform Abbott Laboratories
We think that Dexcom stock (NASDAQ: DXCM) currently is a better pick compared to Abbott stock (NYSE:ABT), despite Dexcom being more expensive of the two. Dexcom trades at about 25x trailing revenues, compared to just 5x for Abbott. Although both...
-
What’s Happening With Abbott Stock?
[Updated: Sep 3, 2021] Abbott Stock Update The stock price of Abbott (NYSE:ABT) has seen a rise of around 20% since early June this year. The company’s Q2 results were comfortably above our as well as the consensus estimates driven by con...
-
Will Abbott Stock Rise Post Q2?
Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22. We expect Abbott to report revenues and earnings above the consensus estimates, driven by continued growth in diagnostics business, along with a rebound in demand ...
-
Will Abbott Stock Continue Its Rally After An 11% Rise In A Month?
The stock price of Abbott Laboratories (NYSE: ABT) has seen an 11% rise over the last twenty-one trading days, while it is up 27% over the last year. Abbott has benefited from a strong demand for Covid-19 testing, which aided its diagnostics b...
-
These Stocks Are Better Priced Compared To Abbott
We believe that there are other stocks in the healthcare sector that are currently better valued than Aboott Laboratories (NYSE: ABT) . Abbott’s current price-to-operating income ratio (P/EBIT) of 30x is much higher than levels of under 12x...
-
What’s Next For Abbott Stock After A 10% Drop Yesterday?
[Updated: 6/2/2021] Abbott Revised Guidance The stock price of Abbott (NYSE:ABT) has seen a large 10% drop over the last five trading days. The decline can be attributed to the company’s announcement of revised earnings guidance for th...
-
After A Large Decline Is Quidel A Better Bet Compared To Abbott Stock?
We think that Quidel (NASDAQ:QDEL) currently is a better pick compared to Abbott (NYSE:ABT) . QDEL stock trades at about 3.1x trailing revenues, compared to around 5.6x for Abbott. Does this gap in Quidel’s valuation make sense? To some ...
-
Forecast Of The Day: Abbott’s Diagnostics Revenue
What? Abbott (NYSE:ABT) Diagnostics Revenue rose from around $7.7 billion in 2019 to $10.8 billion in 2020. We expect the number to rise further to $15 billion in 2021 although it is likely to see a decline in 2022. Why? The surge in revenue ...
-
Here’s Why We Think Abbott Stock Will Rise Post Q1
Abbott stock (NYSE: ABT) is scheduled to report its Q1 2021 results on Tuesday, April 20. We expect Abbott to report revenues in-line and earnings above the consensus estimates, driven by continued demand for Covid-19 testing, along with a reboun...
-
Despite A 2X Rise Over The Last Year Abbott Stock Still Looks Attractive At $120
Abbott Labs (NYSE: ABT) looks attractive at current levels of $120, despite the stock rising 2x from levels of $62 it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks an outperformance compare...
-
These Stocks Can Offer Higher Returns Compared To Abbott Labs
We believe that there are several stocks in the healthcare sector that are better than Abbott Labs (NYSE:ABT) . Abbott’s current market cap-to-operating income ratio of 41x compares with 12x for Emergent Biosolutions (EBS), 19x for Vertex P...
